Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36822670/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The combined data implicate Tregs as a potential therapeutic target in DLBCL, especially in combination with other immunotherapies.
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36819155/
Despite recent advances in the therapy of diffuse large B-cell lymphoma, not otherwise specified (DLBCL), around 30% of patients develop refractory disease or relapse after first-line treatment. Recently, Ars2 was...
Conclusions: Ars2-containing bispecific and IgG1-format BAR-bodies both are new therapeutic formats to target DLBCL cells.
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36399518/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Detection of MRD in ASC samples is associated with a very high relapse risk, justifying alternative treatment strategies or trials of novel consolidation options in those patients. Furthermore, post-ASCT MRD monitoring may facilitate trials evaluating early initiation of treatment at molecular relapse.
Experiences of a Multiethnic Cohort of Patients Enrolled in a Financial Reimbursement Program for Cancer Clinical Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36800640/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Financial reimbursement programs (FRPs) offset out-of-pocket (OOP) expenses from therapeutic clinical trial (TCT) participation. The study explores patients' experience in TCTs after enrollment in a FRP at two academic medical centers, including barriers and opportunities to improve trial participation.
Evolving Applications of Circulating Tumor DNA in Merkel Cell Carcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36765567/
Circulating tumor DNA (ctDNA) is a subset of circulating cell-free DNA released by lysed tumor cells that can be characterized by its shorter strand length and tumor genome-specific information. The...
Conclusions: Leveraging bespoke ctDNA assays may improve physicians' ability to alter treatment plans for non-responsive or high-risk patients. In addition, ctDNA MRD monitoring may allow physicians to treat relapses early before clinically evident disease is present.